View Post

Neratinib Shows Strong Benefit in Early-Stage, Metastatic HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: Neratinib’s (Nerlynx) greatest impact is in the early-stage setting in women with high-risk, HER2-positive breast cancer, said Joyce A. O’Shaughnessy, MD, who added that the agent can also be of benefit to patients with metastatic disease. “The ExteNET data [provide compelling evidence] that giving 1 year of neratinib along with endocrine therapy [in the extended …